drugset / Trial / NCT06569212

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

NCT06569212

Phase 4 Recruiting 20 enrolled Madeleine Puissant MaineHealth · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).

Timeline

Start
2024-09-23
Primary completion
2026-09
Completion
2029-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoprolol Other / unclassified 5 mg Oral
Subject Metoprolol Other / unclassified 25 mg Oral